Disease relevance of Fluorodeoxycytidine

• Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma [1].
• Sequence-specific and mechanism-based crosslinking of Dcm DNA cytosine-C5 methyltransferase of E. coli K-12 to synthetic oligonucleotides containing 5-fluoro-2'-deoxycytidine [2].
• The extent of control of the EMT-6 mammary adenocarcinoma was determined using fractionated radiation (12 irradiations) over a 3-week period using the radiosensitizer 5-chloro-2'-deoxycytidine (CldC) and biomodulators of its metabolism: N-(Phosphonacetyl)-L-aspartate (PALA), tetrahydrouridine and 5-fluoro-2'-deoxycytidine (FdC) [3].

High impact information on Fluorodeoxycytidine

• Both fluorodeoxyuridine and fluorodeoxycytidine were found to be more efficient than trifluorothymidine at comparable concentrations but less efficient than simple folate deprivation in eliciting fragile site expression in lymphocytes [4].
• In view of the 20- to 80-fold elevation of deoxycytidine-5'-phosphate (dCMP) deaminase in many human malignant tumors, we have utilized 5-fluorodeoxycytidine ( FdCyd ) coadministered with tetrahydrouridine ( H4Urd ) as a combination of antitumor agents against two murine solid tumors which possess high levels of dCMP deaminase [5].
• Chemically synthesized 5-fluoro-2'-deoxyuridine 5'-triphosphate and 5-fluoro-2'-deoxycytidine 5'-triphosphate were used efficiently as substitutes for DNA synthesis catalyzed by DNA polymerases alpha or beta from calf thymus [6].
• Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice [7].
• Metabolic channeling of 5-fluoro-2'-deoxycytidine utilizing inhibitors of its deamination in cell culture [8].

Biological context of Fluorodeoxycytidine

• Induction of sister chromatid exchanges by 5-fluorodeoxycytidine: correlation with DNA methylation [9].
• Treating mice of strain C57BL/6Ffm on day 9 of gestation with 10 mg/kg of 5-fluoro-2'-deoxycytidine (FCdR) resulted in malformations of the thoracic vertebral column (ThVC) in 98% of near-term fetuses (Degenhardt et al., 1968) [10].

Anatomical context of Fluorodeoxycytidine

• Uptake measurements were performed up to 48 hr in a TK-expressing cell line and in a control cell line using thymidine (TdR; measured under therapy conditions), fluorodeoxycytidine (FdCyt) and ganciclovir (GCV) [11].

Associations of Fluorodeoxycytidine with other chemical compounds

• The lowest dose ranges at which responses were observed for micronucleus induction were -0.04 microM for 5-fluoro-2'-deoxycytidine, 0.2 microM for 5-azacytidine and 10-20 microM for 5,6-dihydro-5-azacytidine and 6-azacytidine [12].
• The biomodulators of CldC were N-(Phosphonacetyl)-L-aspartate (PALA), an inhibitor of aspartyl transcarbamoylase, 5-fluorodeoxycytidine (FdC), resulting in tumor-directed inhibition of thymidylate synthetase, and H4U, an inhibitor of cytidine deaminase [13].
• Chinese hamster ovary cells grown in medium containing 10 microM 5-fluorodeoxycytidine for forty-eight hours were found to have up to 5% of the deoxycytidine residues of the DNA substituted by this analog [9].

Gene context of Fluorodeoxycytidine

• Thymidylate synthase (TS) is inhibited by 5-fluoro-2'-deoxycytidine 5'-monophosphate (FdCMP) [14].

References